Skip to Content
  • Head Counts and Profits

    I’ve been meaning to link to this article by Frank David at Endpoints, on “leaner and meaner” pharma organizations. For many years now, the st… Read More
  • China’s Biopharma Rise

    This story by Damien Garde at Stat is well worth a look. It goes into a question that people in biopharma have been asking themselves for some years now: when d… Read More
  • Turmoil in Immuno-oncology

    Immuno-oncology! It’s such a big deal, let’s just do what everyone in the field is doing and call it “IO”. The recent successes in this… Read More
  • Zafgen’s Second Act

    F. Scott Fitzgerald was a very good writer, but one of his most famous lines is about as wrong as it can be. It’s actually a cliché to point out the com… Read More
  • Marathon Pharmaceuticals Cashes Out

    You may recall Marathon Pharmaceuticals, the small company that announced plans to sell a long-used steroid treatment (Emflaza, deflazacort) in the US to Duchen… Read More
  • Lose Money Now! Ask Me How!

    Some readers will remember some odd moves in small biotechs like Galena Biosciences, Cytrx, and Lion Biotechnologies, among others. It can be hard to keep track… Read More
  • Bill Ackman, Pompey, and You

    It’s been about a year since Valeant Pharmaceuticals fell apart into a pile of smoldering rubble. As that link details, its biggest investor and biggest f… Read More
Page 3 of 10312345...102030...Last »